[HTML][HTML] Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice
…, C Anders Olson, S Mody, P Spilman, E Gabitzsch… - Scientific Reports, 2021 - nature.com
We have developed a COVID-19 vaccine, hAd5 S-Fusion + N-ETSD, that expresses SARS-CoV-2
spike (S) and nucleocapsid (N) proteins with modifications to increase immune …
spike (S) and nucleocapsid (N) proteins with modifications to increase immune …
A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses
ES Gabitzsch, Y Xu, LH Yoshida, J Balint, RB Gayle… - Immunology letters, 2009 - Elsevier
Adenovirus vectors have been shown to be highly effective as vaccine platforms capable of
inducing both humoral and cell mediated immune (CMI) responses. An Ad serotype 5 vector …
inducing both humoral and cell mediated immune (CMI) responses. An Ad serotype 5 vector …
Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
ES Gabitzsch, Y Xu, LH Yoshida, J Balint, A Amalfitano… - Vaccine, 2009 - Elsevier
Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms in
numerous animal and human clinical studies. The immune response induced by Ad5 …
numerous animal and human clinical studies. The immune response induced by Ad5 …
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
MA Morse, A Chaudhry, ES Gabitzsch… - Cancer Immunology …, 2013 - Springer
First-generation, E1-deleted adenovirus subtype 5 (Ad5)-based vectors, although promising
platforms for use as cancer vaccines, are impeded in activity by naturally occurring or …
platforms for use as cancer vaccines, are impeded in activity by naturally occurring or …
Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA
ES Gabitzsch, Y Xu, JP Balint, ZC Hartman… - Cancer Immunology …, 2010 - Springer
Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it expresses
inserted transgenes robustly and augments the innate immune response. Strategies to improve …
inserted transgenes robustly and augments the innate immune response. Strategies to improve …
[HTML][HTML] The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
ES Gabitzsch, KY Tsang, C Palena, JM David… - Oncotarget, 2015 - ncbi.nlm.nih.gov
… Elizabeth S. Gabitzsch is a shareholder and employee of Etubics and has stock options in
the Company. Adrian Rice is an employee of Etubics and has stock options in the Company. …
the Company. Adrian Rice is an employee of Etubics and has stock options in the Company. …
An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
…, YE Latchman, JP Balint, JH Lee, ES Gabitzsch… - Cancer gene …, 2015 - nature.com
We have investigated if immunotherapy against human papilloma virus (HPV) using a viral
gene delivery platform to immunize against HPV 16 genes E6 and E7 (Ad5 [E1-, E2b-]-E6/E7) …
gene delivery platform to immunize against HPV 16 genes E6 and E7 (Ad5 [E1-, E2b-]-E6/E7) …
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors
Human papillomaviruses (HPVs) are the causative factor for> 90% of cervical cancers and
25% of head and neck cancers. The incidence of HPV positive (+) head and neck squamous …
25% of head and neck cancers. The incidence of HPV positive (+) head and neck squamous …
A next generation bivalent human Ad5 COVID-19 vaccine delivering both spike and nucleocapsid antigens elicits Th1 dominant CD4+, CD8+ T-cell and neutralizing …
…, S Buta, M Martin-Fernandez, B Morimoto, E Gabitzsch… - BioRxiv, 2020 - biorxiv.org
In response to the health crisis presented by the COVID-19 pandemic, rapid development of
safe and effective vaccines that elicit durable immune responses is imperative. Recent …
safe and effective vaccines that elicit durable immune responses is imperative. Recent …
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA …
JP Balint, ES Gabitzsch, A Rice, Y Latchman… - Cancer Immunology …, 2015 - Springer
… Elizabeth S. Gabitzsch is a shareholder and employee of Etubics and has stock options in
the Company. Adrian Rice is an employee of Etubics and has stock options in the Company. …
the Company. Adrian Rice is an employee of Etubics and has stock options in the Company. …